SCHEMBL8914916

SCHEMBL8914916

Cc1c(SCCN2CCc3ccccc3C2)ccnc1CSc1nc2ccccc2[nH]1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.49
CYP1A2 P05177 2/20 0.49
CYP2D6 P10635 2/20 0.49
CYP2C9 P11712 2/20 0.49
CYP2C19 P33261 2/20 0.49
NPC1 O15118 2/20 0.49
CYP3A4 P08684 1/20 0.49
HTR1A P08908 1/20 0.46
DRD2 P14416 1/20 0.46
HTR7 P34969 1/20 0.46
HRH1 P35367 1/20 0.46
DRD3 P35462 1/20 0.46
GRIN2A Q12879 1/20 0.42
GRIN2B Q13224 1/20 0.42
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
CYP2E1 P05181 1/20 0.41
CYP2C8 P10632 1/20 0.41
CYP2B6 P20813 1/20 0.41
SOAT1 P35610 4/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8915109 0.92 RAB9A (0.43) RAB9ACYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL8915115 0.92 RAB9A (0.40) RAB9ACYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL8914888 0.90 DRD2 (0.42) RAB9ACYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL8914889 0.90 GRIN2B (0.47) RAB9ACYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL8915325 0.86 RAB9A (0.55) RAB9ACYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL8915135 0.85 RAB9A (0.54) RAB9ACYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL8915606 0.85 RAB9A (0.69) RAB9ACYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL8923805 0.85 CYP2C9 (0.59) RAB9ACYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL8915844 0.82 RAB9A (0.50) RAB9ACYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL8916879 0.80 RAB9A (0.60) RAB9ACYP1A2CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0644191-A1 PYRIDINE COMPOUND AND MEDICINAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1995-03-22 EP claimed
US-20180028517-A1 BENZIMIDAZOLE SULFIDE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF TUBERCULOSIS ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL) (CH) 2018-02-01 US disclosed
US-5616581-A BACTERICIDES YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1997-04-01 US disclosed
US-5504082-A BACTERICIDE FOR HELICOBACTER, ANTIULCER AGENT, GASTRIC ACIDSUPPRESSOR YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1996-04-02 US disclosed
EP-0644191-A1 PYRIDINE COMPOUND AND MEDICINAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1995-03-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180028517-A1 BENZIMIDAZOLE SULFIDE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF TUBERCULOSIS TST, SQOR, CBS RAB9A 4090/4885CYP1A2 545/4885CYP2D6 426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.